Nimodipinum [Inn-Latin]
Brand names,
Nimodipinum [Inn-Latin]
Analogs
Nimodipinum [Inn-Latin]
Brand Names Mixture
Nimodipinum [Inn-Latin]
Chemical_Formula
C21H26N2O7
Nimodipinum [Inn-Latin]
RX_link
http://www.rxlist.com/cgi/generic2/nimodip.htm
Nimodipinum [Inn-Latin]
fda sheet
Nimodipinum [Inn-Latin]
msds (material safety sheet)
Nimodipinum [Inn-Latin]
Synthesis Reference
No information avaliable
Nimodipinum [Inn-Latin]
Molecular Weight
418.44 g/mol
Nimodipinum [Inn-Latin]
Melting Point
No information avaliable
Nimodipinum [Inn-Latin]
H2O Solubility
No information avaliable
Nimodipinum [Inn-Latin]
State
Solid
Nimodipinum [Inn-Latin]
LogP
3.152
Nimodipinum [Inn-Latin]
Dosage Forms
Capsules
Nimodipinum [Inn-Latin]
Indication
For the treatment of subarachnoid bleeding.
Nimodipinum [Inn-Latin]
Pharmacology
Nimodipine belongs to the class of pharmacological agents known as calcium channel blockers. Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured congenital aneurysms who are in good neurological condition post-ictus (e.g., Hunt and Hess Grades I-III). The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. Nimodipine inhibits calcium ion transfer into these cells and thus inhibits contractions of vascular smooth muscle. In animal experiments, nimodipine had a greater effect on cerebral arteries than on arteries elsewhere in the body perhaps because it is highly lipophilic, allowing it to cross the blood brain barrier.
Nimodipinum [Inn-Latin]
Absorption
No information avaliable
Nimodipinum [Inn-Latin]
side effects and Toxicity
No information avaliable
Nimodipinum [Inn-Latin]
Patient Information
No information avaliable
Nimodipinum [Inn-Latin]
Organisms Affected
Humans and other mammals